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Poor healing of tendon and ligament lesions often results in early retirement of sport 
horses. Therefore, regenerative therapies are being explored as potentially promising 
treatment for these injuries. In this study, an intralesional injection was performed with 
allogeneic tenogenically induced mesenchymal stem cells and platelet-rich plasma 
5–6  days after diagnosis of suspensory ligament (SL) (n =  68) or superficial digital 
flexor tendon (SDFT) (n = 36) lesion. Clinical, lameness and ultrasonographic evalu-
ation was performed at 6 and 12 weeks. Moreover, a survey was performed 12 and 
24 months after treatment to determine how many horses were competing at original 
level and how many were re-injured. At 6 weeks, 88.2% of SL (n = 68) and 97.3% 
of SDFT lesions (n  =  36) demonstrated moderate ultrasonographic improvement. 
At 12 weeks, 93.1% of SL (n = 29) and 95.5% of SDFT lesions (n = 22) improved 
convincingly. Moreover, lameness was abolished in 78.6% of SL (n = 28) and 85.7% 
(n = 7) of SDFT horses at 12 weeks. After 12 months (n = 92), 11.8% of SL and 12.5% 
of SDFT horses were re-injured, whereas 83.8 of SL and 79.2% of SDFT returned 
to previous performance level. At 24 months (n = 89) after treatment, 82.4 (SL) and 
85.7% (SDFT) of the horses returned to previous level of performance. A meta-analysis 
was performed on relevant published evidence evaluating re-injury 24 months after 
stem cell-based [17.6% of the SL and 14.3% of the SDFT group (n =  89)] versus 
conventional therapies. Cell therapies resulted in a significantly lower re-injury rate of 
18% [95% confidence interval (CI), 0.11–0.25] 2 years after treatment compared to 
the 44% re-injury rate with conventional treatments (95% CI, 0.37–0.51) based on 
literature data (P < 0.0001).
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inTrODUcTiOn
Tendon and ligament lesions are very common injuries in sport 
and pleasure horses and often result in early retirement. The 
most frequently affected tendon in horses is the superficial digital 
flexor tendon (SDFT) (1). However, the type and frequency of 
tendon or ligament injuries depends on the discipline and the 
competitive level of the horse. Indeed, show jumping horses have 
a higher risk for SDFT tendinitis in the forelimb, whereas dres-
sage horses are more subjected to hind limb suspensory ligament 
(SL) desmitis (1, 2).
The healing process of tendon and ligaments can be divided 
into four stages: an acute inflammatory phase, a subacute repara-
tive phase, a collagen phase, and a chronic remodeling phase 
(3). It has been hypothesized that the most indicated moment 
for treatment is the transition between the inflammatory phase 
and the subacute reparative phase (3, 4), which is characterized 
by scar tissue production and collagen type III deposition by the 
fibroblasts. This tissue is weaker and less elastic than tendon tis-
sue, which increases the risk of re-injury of the lesion site (3–8). 
The fibroplasia usually begins around the seventh day after the 
initial lesion, and therefore, the most adequate time of injection 
with stem cells would be around the fifth or the sixth day after 
injury (9–11).
Over the past years, tendon treatments with stem cells from 
different sources have been reported. Carvalho et al. described 
the use of autologous adipose tissue-derived mesenchymal stem 
cells (MSCs) suspended in a platelet concentrate for the treatment 
of induced SDFT tendinitis during a randomized controlled trial 
in eight mixed breed horses. Compared to the control group, a 
prevention of lesion progression, a better organization of col-
lagen, and less inflammation were observed in the treatment 
group (12). Bone marrow (BM) is another frequently used 
source for MSCs. Smith et al. demonstrated favorable effects of 
autologous BM-derived MSCs on tendon healing in naturally 
occurring SDFT tendinitis in 12 horses (13). More precisely, the 
healed tendon of the horses in the treated group showed less 
stiffness and a better histological organization than the saline 
control group and reflected a trend to normalization of the 
tendon structure, which was significantly better than the saline 
control group. Despite these promising outcomes, the use of the 
horse’s own (autologous) MSCs is not always feasible in the field, 
and allogeneic MSCs can offer a valuable and more practical 
alternative. Indeed, allogeneic stem cells have been described 
for the treatment of different types of orthopedic injuries. Van 
Loon et al. described beneficial results after allogeneic umbilical 
cord blood (UCB)-derived MSC treatment of tendon and liga-
ment injuries in 52 horses, and more precisely 77% (40 horses) 
regained their initial or a higher level of performance at 6 months 
after treatment than before the injury (14). In 2013, Ricco et al. 
described the use of allogeneic adipose tissue-derived MSCs 
combined with platelet-rich plasma (PRP) for the treatment of 
SDFT tendinitis in 19 horses. In this study, 89.5% of the horses 
returned to their previous competing level after a follow-up of 
24 months (15).
Multipotent MSCs have been reported to cause ectopic 
bone formation after their transplantation in rabbit tendons 
(16, 17). However, to date, no ectopic tissue formation after MSCs 
injections has been described in horses. Fahy et al. suggested the 
use of predifferentiated MSCs toward the chondrocyte lineage to 
avoid inhibition of MSC chondrogenic differentiation by syno-
vial fluid, factors, and macrophages present in the synovium of 
osteoarthritic joints (18). The safe use of tenogenically induced 
allogeneic MSCs in combination with PRP has been reported 
before in horses with SDFT and SL lesions (19). Moreover, a recent 
study of 20 horses with degenerative joint disease examined the 
clinical outcome after treatment with PRP alone, MSCs alone, 
or a combination of both PRP and MSCs. The latter pointed out 
that the combination of PRP + MSCs demonstrate significantly 
better clinical outcomes at short- and long-term in comparison 
with single treatments (6  weeks to 12  months) (20). However, 
long-term efficacy of a combination therapy of PRP and MSCs to 
treat tendon and ligament lesions in a large group of animals is 
indispensable from a clinical point of view.
Finally, the timing of the intralesional injection with MSCs 
depends on the source of MSCs. Autologous MSCs require a 2- to 
3-week period of culture before implantation in the lesion, pos-
sibly compromising the treatment outcome. Currently, the time 
between harvesting and injection varies from 7 to 45 days (12). 
The use of allogeneic stem cells gives the possibility to prepare 
and characterize MSCs in advance and thus having stem cells 
available at any time.
The aim of our study is to evaluate the combined use of 
tenogenically induced MSCs and PRP in a large group of horses 
with tendon and ligament injuries. On the basis of preliminary 
data, we hypothesized that this combination for the treatment of 
SDFT tendinitis and SL desmitis would be safe and effective in 
comparison with reported conservative treatments.
MaTerials anD MeThODs
clinical case selection
In this study, 68 horses with SL lesions and 36 horses with 
SDFT tendinitis were included. A total of 104 dressage and 
show jumping horses were ultrasonographically and clinically 
examined before entering in the study in two different veteri-
nary practices. A 7.5-MHz linear ultrasound probe was used to 
evaluate the injured region. A complete examination of the 
SDFT or SL was performed during each ultrasound examina-
tion with both transverse and longitudinal scans. The scoring 
system for evaluating ultrasound images and clinical soundness 
was adapted from the previous study by Beerts et al. (6) and can 
be found in Table 1.
Only horses with a lameness of one to three of five according 
to the American Association of Equine Practitioners (AAEP) 
grading system were allowed to participate in the study. More-
over, ultrasound imaging had to identify a clear core lesion 
present in the SL or SDFT, and no other lesions at other loca-
tions were allowed in this study. The lesion of the SL had to be 
restricted to one of the branches or to the origin.
Approval of the ethics committee was obtained (EC_2012_001) 
for blood sampling of the donor horse. The Federal Public Service 
of Health approved the Ethics Committee and granted the 
TaBle 1 | Different scoring systems used to evaluate SL and SDFT lesion 
healing.
a score
0 = 0% improvement or no ultrasonographic improvement
 = Anechoic lesion + absence of fiber alignment
1 = 20% improvement or minor ultrasonographic improvement
 = Hypoechoic areas/diffuse decrease in echogenicity + lack of parallel pattern
2 = 40% improvement or modest ultrasonographic improvement
 = Multiple areas with decreased echogenicity + increased parallel fiber pattern
3 = 60% improvement or moderate ultrasonographic improvement
 = Demarcation with healthy tissue less distinct + increased parallel fiber pattern
4 = 80% improvement or convincing ultrasonographic improvement
 = Hardly any demarcation with healthy tissue + close to total fiber alignment
5 = 100% improvement or no ultrasonographic abnormalities
 = Normal echogenicity + (almost) normal parallel fiber alignment
B score
0 = Lameness not perceptible under any circumstances
1 = Lameness is difficult to observe and is not consistently apparent, regardless 
of circumstances (e.g., under saddle, circling, inclines, hard surface)
2 = Lameness is difficult to observe at a walk or when trotting in a straight line 
but consistently apparent under certain circumstances
3 = Lameness is consistently observable at a trot under all circumstances
4 = Lameness is obvious at a walk
5 = Lameness produces minimal weight bearing in motion and/or at rest or a 
complete inability to move
c score
00 = Failure to return to work/re-injury
0 = Rehabilitating 
1 = Return to work
2 = Return to previous level of work
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is considered to be possible thanks to the phenotypic stability of 
PB-MSCs from P5 up to P10 (21, 23, 24). After trypsinization, 
all the cells were resuspended in 1 ml DMEM low glucose (Life 
Technologies) with 10% of dimethyl sulfoxide (Sigma). The 
samples were stored at −80°C until all quality controls [sterility 
testing; mycoplasma testing; endotoxine testing; flow cytometry 
for CD29, CD44, and major histocompatibility complex (MHC) 
II; and viability staining] were completed.
For PRP preparation, 300 ml PB was taken in a citrate phos-
phate dextrose adenine-1 single blood bag (Terumo®). Platelets 
were purified by means of subsequent centrifugation steps as pre-
viously reported (25) until more than 80% platelets were obtained 
at a concentration of more than 100 × 106 platelets in 1 ml plasma. 
The leukocyte count of PRP was 0.5% (<100 leukocytes/μl). 
Different batches of PRP were necessary to produce sufficient 
excipient for all the treatments. Allogeneic cells and allogeneic 
PRP were shipped on dry ice for clinical application.
Treatment
The horses were injected approximately 5–6 days after the lesion 
occurred. When the diagnosis of SL or SDFT lesion was estab-
lished, an intravenous injection of a sedative agent was performed, 
and the injection site was thoroughly cleaned and disinfected. 
For all of the 104 patients included in this study, an intralesional 
ultrasound-guided injection (Figure  1) with allogeneic teno-
genically induced MSCs and PRP was performed by an equine 
orthopedic specialist. After thawing, 1  ml of PRP (containing 
between 100,000,000 and 150,000,000 platelets per treatment) 
and 1 ml of tenogenically induced PB-derived MSCs (with the 
number of stem cells ranging from 2,000,000 to 3,000,000 with a 
viability of at least 50% due to storage and frozen transport) were 
mixed in one syringe before the ultrasound-guided intralesional 
injection. The same dose was used for all lesion sizes included in 
the study. For the next 3–5 days, horses were administered oral 
non-steroidal anti-inflammatory drugs (NSAIDs) consisting of 
1–2 g phenylbutazone.
evaluation Protocol
The same independent veterinarians (MS, BS, and AV) were 
asked to report the results of the examination of each horse in 
a standardized follow-up document as demonstrated in Table 1. 
First, an “A score” regarding the clinical and ultrasonographic 
improvement had to be given to all the horses by using the initial 
ultrasound images as comparison. This score ranges from 0 to 
5 (0 meaning no ultrasonographic improvement and 5 meaning 
100% ultrasonographic improvement) and is an addition of two 
previously described ultrasonographic grading scales, more 
precisely an echogenicity scale (0 meaning anechoic lesion and 
5 meaning normal echogenicity) and fiber arrangement scale 
(0 meaning absence of fiber alignment and 5 meaning normal 
parallel fiber alignment) (26). For a number of these horses, a 
“B score,” relating to the lameness evaluation [following the AAEP 
grading system (20)], and a “C score,” regarding the allowed 
level of exercise, were also given (Table  1). Unfortunately, not 
all veterinarians recorded a “B and C score” for the examined 
horses, so the quantity of these scores is lower than the quantity of 
company with a laboratory recognition number (LA1700607), 
allowing the housing and handling of experimental animals 
providing blood for the isolation of stem cells.
The owners were informed about the study and gave their 
consent for their horses participating in the study.
Msc isolation, Tenogenic induction,  
and PrP Preparation
Both tenogenically induced MSCs and PRP were prepared from 
peripheral blood (PB) from a 6-year-old German Warmblood 
horse according to good manufacturing practices and character-
ized as previously described (21–23).
Briefly, 20  ml PB was collected aseptically from the vena 
jugularis in ethylenediaminetetraacetic acid (EDTA) tubes for 
MSC isolation from one donor. Subsequently, the blood was 
centrifuged, and the buffy coat was collected for gradient cen-
trifugation. After washing, 20 million peripheral blood mono-
nuclear cells were seeded per T75 flask and cultured until 60% 
confluency was reached corresponding with 0.18–0.32 million 
MSCs. Trypsinization was performed with 0.25% trypsin-EDTA 
until passage 5 (P5) was reached. All batches between P6 and 
P8 were seeded in T75 flasks and tenogenically induced by sup-
plementing tendogenic growth factors to the expansion medium 
until 80% confluency was reached and tenogenic differentiation 
markers were upregulated (19, 21, 22). A higher passage was used 
to allow upscaling in future cell manufacturing processes, which 
FigUre 1 | The ultrasound image indicates the needle inserted for injection. A standardized rehabilitation program was applied as strictly as possible starting from 
the evaluation at 6 ± 2 weeks (Exam 1).
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“A scores” recorded. This scoring system was considered an objec-
tive manner in which to report the data.
Follow-up and rehabilitation
The first week following the treatment, all treated horses were 
clinically examined daily by a veterinarian, and more precisely 
they were examined for lameness at a walk and pain, heat, and 
swelling at the injection site. All horses had to walk for 5 min 
three to four times a day until the first scoring evaluation of 
the veterinarian at week 6 ± 2 (Exam 1). A clinical evaluation, 
lameness assessment, and ultrasonography were performed. 
If the healing progressed successfully, the amount of exercise 
of the horse could be increased (an A score of 3 = at least 60% 
improvement). On the other hand, if there was no significant 
improvement, the animal had to continue walking. A second 
examination was performed in 51 (29 SL and 22 SDFT) of the 
104 horses at week 12 ±  4 (Exam 2). Unfortunately, a number 
of owners failed to present their horse for the second examina-
tion, which reduces the number of scores collected at that time 
point. Again, depending on the degree of improvement (denoted 
by an A score of 4 = at least 80% improvement), an increase in 
exercise was allowed. More details on the rehabilitation program 
can be found in Figure 1. Horses that showed moderate or less 
improvement (denoted by an A score of 3 or less = 60% improve-
ment or moderate ultrasonographic improvement) received a 
second injection of tenogenically induced PB-derived MSCs in 
combination with PRP at the second examination. During the 
first 2 weeks following injection, these horses were hand-walked 
for 5 min three to four times per day, and then they had to walk 
for 20 min and trotted for 5 min until 6 months after the initial 
injection. After 6 months, the horses were allowed to go back into 
full work. Furthermore, at 12 (exam 3) and 24 months (exam 4) 
after treatment, a survey was performed to determine how many 
horses were competing at their original level again. More pre-
cisely, the owners were asked if the horses were competing at the 
same level again. If the horse was not competing, the owners were 
asked for the reason for retirement (re-injury, other reason). The 
outcome of 68 horses with SL lesions and 24 horses with SDFT 
lesions could be obtained at 12 months (n = 92) after treatment 
and of 68 horses with SL lesions and 21 horses with SDFT lesions 
after 24 months (n = 89).
statistical analysis
Percentage of re-injury was calculated by dividing the number of 
horses that relapsed and retired due to an injury of the treated SL 
or SDFT after 24 months by the total number of evaluated horses 
multiplied by 100. Horses that were not available for follow-up 
or retired due to other reasons were not included in this re-injury 
calculation. For the meta-analysis, the literature was first reviewed 
for publications on the treatment of similar equine tendon and 
ligament injuries, using search terms such as “horses,” “stem 
cells,” “allogeneic,” “autologous,” “PRP,” “SL,” and “SDFT” and in 
the Web of Science database, PubMed, and Google search. All 
case studies consisting of stem cell-based therapies for SDFT 
FigUre 2 | Representative transverse (arrows) and longitudinal (circles) images of superficial digital flexor tendon (SDFT) (1) and suspensory ligament (SL) (2) at the 
moment of acute lesion (day 0) (a), at 6 weeks after treatment (B) with an A score of 3 (at least 60% improvement), and at 12 weeks after treatment (c) with an A 
score of at least 4 (at least 80% of improvement). The arrows and circles indicate the location of the lesion.
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and SL treatment were included in one group of the analysis. All 
clinical results of SDFT and SL treatments with medical standard 
of care were included in the second group. Furthermore, the 
re-injury rates were compared between different stem cell treat-
ments (including this study) and conventional treatments using 
the random effects model and the Wald test. The meta-analysis 
results are presented in a forest plot.
resUlTs
Follow-up and rehabilitation
Following the injection, none of the horses showed any adverse 
reactions. NSAIDs were administered for 3–5  days and might 
have reduced any possible swelling due to the injection. 
At 6 ± 2 weeks (Exam 1), 88.2% of the horses with SL lesions (n = 68) 
received an A score of at least 3 (at least 60% improvement). In the 
group of horses suffering from SDFT tendinitis, 98.2% received an 
A score of at least 3 (n = 36) (Figure 2). Of the 104 horses with SL 
or SDFT lesion, 42 horses received a B score and 45 horses received 
a C score at Exam 1. Regarding the B score, 82.3% of the SL group 
and 87.5% of the SDFT group presented no or very light lameness 
(score 0–1). This demonstrated an early clinical improvement 
in most of the horses. As prescribed by the veterinarian, 75% of 
horses with SL lesion and 88.9% of horses with SDFT tendinitis 
were rehabilitating (C score of 0) at Exam 1 (Table 2).
A total of 51 horses (n =  29 horses with SL lesion; n =  22 
horses with SDFT tendinitis) were subjected to an examina-
tion at 12 ±  4  weeks (Exam 2), In the SL group, 41.4% of the 
horses received an A score of 4 and 51.7% an A score of 5 (score 
4  +  5  =  93.1%). In the SDFT group, similar A scores were 
observed in 45.5 and 50.0% of the horses (score 4 + 5 = 95.5%), 
respectively (Figure  2). The AAEP lameness evaluation or B 
score and the C score were documented in 28 horses with SL 
lesion and 7 horses with SDFT tendinitis. In 78.6% of the horses 
with SL lesion and 85.7% of the horses with SDFT tendinitis, no 
more lameness was observed (score 0) at Exam 2. Finally, 57.1 
(= 35.7 + 21.4) and 71.4% of the horses returned to work in SL 
group (score 1 + 2) and SDFT group, respectively (Table 2) at 
12 weeks (Exam 2).
At 12 months after treatment, 83.8% (n = 57) of SL horses 
(n = 68) were competing at initial level and 11.8% (n = 8) were 
re-injured, whereas 79.2% (n =  19) of SDFT horses (n =  24) 
returned to previous level and 12.5% (n = 3) were re-injured. 
After 24 months, 82.4% (n = 56) of the horses with SL lesions 
(n =  68) were competing at their initial level; however, 22% 
(n = 15) of them [horses who received an A score of 3 or less 
at 12 ± 4 weeks (Exam 2)] received a second injection at Exam 
2 with tenogenically induced PB-derived MSCs before getting 
to previous level. Moreover, 14.7% (n = 10) of the horses in the 
SL group relapsed and were retired, and finally, 2.9% (n = 2) 
of the horses had to quit sport for multiple reasons. In the 
second group (SDFT, n =  21), 85.7% (n =  18) of the horses 
were competing at their initial level after 24 months, yet 33.3% 
(n =  7) of the competing horses received a second injection 
and 14.3% (n = 3) of the horses with SDFT lesions were retired 
after a relapse.
Meta-analysis
The meta-analysis based on the reported stem cell studies includ-
ing this study revealed a highly significant difference between 
stem cell treatment and other treatments (P < 0.0001). The stem 
cell-treated group has a significantly lower re-injury rate equal to 
18% [95% confidence interval (CI), 0.11–0.25] compared to the 
conventional treatments with a re-injury rate equal to 44% (95% 
CI, 0.37–0.51). The odds of re-injury is significantly smaller in the 
stem cell-treated group compared to the conventional treatment 
group (OR = 0.78, 95% CI, 0.71–0.86, P < 0.0001). The results are 
shown in the forest plot in Figure 3.
TaBle 2 | Percentage of treated patients with corresponding A, B, and C scores 
at a 6 ± 2 weeks (Exam 1) (n1) and 12 ± 4 weeks (Exam 2) (n2) and with C 
scores at 12 (Exam 3) and 24 months (Exam 4) after treatment of the suspensory 
ligament (SL) or superficial digital flexor tendon (SDFT) with allogeneic 
tenogenically induced mesenchymal stem cells in combination with platelet-rich 
plasma.
a score (%) 0 1 2 3 4 5
SL Exam 1 n1 = 68 0 0 11.8 29.4 44.1 14.7
Exam 2 n2 = 29 0 0 0 6.9 41.4 51.7
SDFT Exam 1 n1 = 36 0 0 2.8 30.6 52.8 13.9
Exam 2 n2 = 22 0 0 0 4.6 45.5 50.0
B score (%) 0 1 2 3 4 5
SL Exam 1 n1 = 34 35.3 47.1 17.7 0 0 0
Exam 2 n2 = 28 78.6 14.3 3.6 3.6 0 0
SDFT Exam 1 n1 = 8 50.0 37.5 12.5 0 0 0
Exam 2 n2 = 7 85.7 0 14.3 0 0 0
c score (%) 00 0 1 2
SL Exam 1 n1 = 36 0 75.0 22.2 2.8
Exam 2 n2 = 28 0 42.9 35.7 21.4
Exam 3 n3 = 68 11.8 2.9 1.5 83.8
Exam 4 n4 = 68 17.6 0 0 82.4
SDFT Exam 1 n1 = 9 0 88.9 11.1 0
Exam 2 n2 = 7 0 28.6 71.4 0
Exam 3 n3 = 24 12.5 8.3 0 79.2
Exam 4 n4 = 21 14.3 0 0 85.7
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DiscUssiOn
In this study, 68 horses with SL lesions and 36 horses with SDFT 
tendinitis were treated with tenogenically induced PB-derived 
MSCs combined to PRP. No adverse reactions could be observed 
in any of the horses; however, it should be emphasized that 
NSAIDs were provided for 3–5  days after the intralesional 
injection to assist in reducing the originally present swelling and 
pain. Nevertheless, it has been previously reported that alloge-
neic MSCs do not induce an immune response and associated 
discomfort in the receiver horses. Indeed, in a previous study, 
no significant immune reaction was reported in the SL and 
SDFT of 25 horses after intralesional treatment with tenogeni-
cally induced PB-derived MSCs without administering NSAIDs 
(19). Moreover, no local adverse reaction was reported after 
allogeneic tenogenically induced MSC treatment of four horses 
with desmitis of the accessory ligament of the deep digital flexor 
tendon (6). Although the latter horses were treated with NSAIDs 
for 5  days before the injection with MSCs, no more NSAIDs 
were administered after treatment. In another study, 19 horses 
affected by SDFT tendinitis were treated with an association of 
allogeneic adipose tissue-derived MSCs and PRP without the 
administration of NSAIDs, and again, there was no proof of any 
local immunological reaction (absence of heat, swelling, pain, or 
lameness) in the treated horses (15). A study comparing the effects 
of autologous mesenchymal progenitor cells (MPCs), allogeneic 
MPCs, or BM supernatant alone on induced SDFT tendinitis 
could not show differences in cell-mediated immune responses 
between different stem cell sources. The horses received a single 
intravenous injection of NSAIDs before the induction of the 
lesion and antibiotics for several days (30). Finally, Carrade et al. 
reported a similar response in the joint following an intraarticular 
injection of allogeneic MSCs compared to autologous MSCs (31).
All the aforementioned work indicates that there do not 
appear to be remarkable differences in safety between autolo-
gous and allogeneic MSCs. It is possible that MSCs may have 
the ability to restrain immune cells and to reduce the production 
of pro-inflammatory cytokines (32, 33). However, repeated 
intravenous injections of allogeneic equine MSCs have been 
shown to result in elevated numbers of circulating CD8+ T cells, 
suggesting a mild alloantigen-directed cytotoxic response (34). 
Nevertheless, there was no indication for any organ toxicity 
or systemic inflammatory response, and another study also 
reported no clinical issues after single or repeated intravenous 
injections in 291 horses (35). Also in this study, no adverse event 
was noticed after a second injection in 15 horses with SL and 
7 horses with SDFT lesions. A recent study reported elevated 
synovial total nucleated cell counts after repeated intraarticular 
injections of allogeneic BM-derived MSCs (36). However, the 
clinical relevance remains to be demonstrated (37) because 
allogeneic MSCs would not enhance a hypersensitivity response 
according to other researchers (38). On the other hand, Owens 
et al. reported the presence of anti-MSCs antibodies in the serum 
of 37% of horses injected with allogeneic BM- or adipose tissue-
derived MSCS. Currently, the significance of these antibodies 
is unknown and warrants further research in case of repeated 
injections (39). In addition, an in vitro study described a cyto-
toxic antibody response in recipient horses after the injection 
of allogeneic MHC-mismatched BM-derived MSCs (40). This 
indicates that MHC levels are crucial for allogeneic transplan-
tations and warrant analyses before clinical use in horses. In a 
study investigating the antibody response to allogeneic MSC 
transplantation after an intradermal injection of allogeneic MSCs 
into the neck of six horses, Pezzanite et al. described the capac-
ity of allogeneic MSCs to elicit antibody responses (41). In this 
study, we used a considerably lower amount of MSCs (2–3 × 106 
MSCs per ml) compared to other studies [10 × 106 MSCs per ml 
(36), 25–80 ×  106 MSCs per injection (39), and 30 ×  106 or 
50 × 106 MSCs per injection (41)]. This could explain the low 
immunogenicity and the absence of observable adverse events 
in the horses that were injected in this study. Finally, Berglund 
et al. described the downregulation of MHC I and MHC II on 
equine BM-derived MSCs without alteration of other phenotypic 
cell surface markers when culturing the cells in specific media, 
suggesting that media selection could be an interesting option 
to guaranty the safe use of allogeneic MSCs (42). Nevertheless, 
more robust in  vivo studies are required to detail the precise 
immunologic effect of allogeneic cell treatment in the horse.
The PRP used in our study is leukocyte-poor (LP) PRP. 
Nevertheless, to date, the optimal combination of platelet and 
leukocytes is not known. However, different in vitro studies sug-
gested a lower expression of pro-inflammatory cytokines after the 
intratendinous injection of leukocyte-reduced PRP compared to 
leukocyte-rich PRP (43, 44). Furthermore, persistent inflamma-
tion of the tendon engenders more scar tissue formation resulting 
in inferior tendon repair (44). Another study described improved 
functional outcome scores after the injection of LP-PRP in the 
FigUre 3 | Forest plot representing a comparison of the re-injury rates between different stem cell treatments from the current study (Beerts) and other studies  
(15, 27, 28) with conventional treatments (29) using a meta-analytic approach based on the random effects model. The squares represent the re-injury rates of 
individual studies, with the whiskers corresponding to the 95% confidence interval (CI). The diamonds correspond to the re-injury rates and 95% CI of the two 
subgroups and overall.
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treatment of knee osteoarthritis in human when compared to 
hyaluronic acid or placebo. This difference was not observed after 
the injection of leukocyte-rich PRP (45).
At 6 and 12 weeks, the clinical and ultrasonographic improve-
ments of more than 88% of the treated horses with SL lesions or 
SDFT tendinitis seemed promising. Nevertheless, a quantitative 
ultrasonographic and lameness assessment would have provided 
a more objective tendon evaluation. After 12 months (n = 92), 
83.8% of SL and 79.2% of SDFT horses returned to previous level 
of performance. Finally, 24  months after treatment (n =  89), 
82.4% of the horses with SL lesions and 85.7% of the horses with 
SDFT lesions were competing at their initial level. These results 
are comparable, yet a bit lower than those obtained by Ricco 
et al. on 19 horses with SDFT tendinitis (89.5% to original level 
after 24 months) (15), by Del Bue et al. on 16 horses with SDFT 
tendinitis (87.5% back to work at 23 weeks) (27), and finally by 
Toricelli et  al. on 13 horses with SDFT and SL lesions (84.6% 
back to competition after 12 months) (46). In our study, 22 and 
33.3% of the horses affected with SL lesions and SDFT tendinitis, 
respectively, did also require a second treatment at 12 ± 4 weeks 
(Exam 2) before returning to the original competing level. 
However, these horses were all high-level athletes, and therefore, 
the lower return to previous level and second treatments were 
perhaps not surprising. Van Loon et  al. reported the necessity 
of a second injection of allogeneic UCB MSCs in 4.3% of the 23 
horses with SDFT lesions and 18.2% of the 22 horses with SL 
lesions (14). Although this is considerably lower than the results 
in this study, it should be mentioned that the re-injury rate was 
considered at 6 months after treatment only, and no results are 
available at 24  months, which would have provided valuable 
comparative data.
In this study, 11.8% of SL and 12.5% of SDFT horses were 
re-injured after 12 months (n = 92) and 17.6% and 14.3% were 
re-injured at 24  months, respectively (n =  89). Unfortunately, 
tendon and ligament injuries have a rather poor prognosis with 
conventional treatment. The meta-analysis demonstrated a 
significantly lower re-injury rate of 18% (95% CI, 0.11–0.25) in 
the stem cell-treated group compared to conventional treatments 
with a re-injury rate of 44% (95% CI, 0.37–0.51) (P <  0.001). 
Different non-blinded case series with different stem cell 
sources for both tendon (SDFT) and ligament (SL) lesions have 
been included in the meta-analysis. This has a lower conclusive 
value in comparison with a placebo-controlled, double-blinded 
clinical trial with all animals treated and rehabilitated under the 
same circumstances with the possibility of a direct comparison 
between different treatment groups. Nevertheless, overall results 
from conservative treatment studies demonstrate considerably 
higher re-injury rates than all stem cell studies considered for the 
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meta-analysis. Indeed, in one study, the re-injury rate of proximal 
SL desmitis was 46% in jumping horses and 37% in dressage 
horses (47). Furthermore, a two-part study conducted by Dyson 
on horses affected with SDFT tendinitis resulted in a re-injury 
rate after 2 years ranging from 42.5 to 44.4% in a first group of 135 
horses treated conservatively or medically. In the second group of 
68 horses treated with beta aminopropionitrile fumarate, 16% of 
the horses relapsed in the treated limb, but, when the uninjured 
limb was taken into consideration, the re-injury rate was up to 
45.6%, which is comparable to the re-injury rate reported in the 
first group (29).
In this study, the MSCs were combined with PRP for its 
capacity to provide growth factors, which potentiate the early 
healing of the lesion by stimulating angiogenesis and by enhan-
cing MSC proliferation (27). Indeed, beneficial clinical effects 
of the combination of PRP and MSCs in comparison to MSCs 
alone have been described multiple times after treatment of 
tendon lesions with allogeneic adipose tissue-derived MSCs 
(15, 27) or BM mononucleated cells (27) combined with autolo-
gous PRP. Nevertheless, it should be emphasized that PRP alone 
may also have beneficial effects on tendon healing (48). This 
definitely warrants further investigation to determine whether 
the observed results in this study are due to the MSCs or PRP or 
the combination of both.
As previously mentioned, the timing of the intralesional 
injection depends on the source of MSCs (autologous versus 
allogeneic). In this study, the MSCs were injected 5–6 days after 
the initial lesion, more precisely after the acute inflammatory 
response but before the formation of fibrous tissue (3).
Even though the results of this study seem promising, the 
study has some limitations. First, it was not blinded, and there 
was no untreated or placebo-treated control group. However, 
considering it was not a preclinical study but an evaluation of 
a large group of sport horses treated by independent veterina-
rians, it would be difficult to convince the owners to include 
their animal in the placebo group. Nevertheless, future stud-
ies should include a group with at least best supportive care 
or PRP treatment alone as a control group. To put these data 
in a larger context and still make valuable comparisons, the 
aforementioned meta-analysis was performed comparing the 
re-injury rate of stem cell-based therapies (including our data) 
and conventional therapies. Our data comply with results from 
all other studies, and the stem cell-based therapies have a sig-
nificantly lower re-injury rate than the conventional therapies. 
Nonetheless, predifferentiating MSCs remains a sensible strat-
egy to reduce the risk of unwanted cell formation in an inflamed 
tendon environment as reported in rabbits before (16, 17) and 
to direct the cells toward the tissue that needs regeneration. 
Comparing the re-injury results of SDFT lesions in this study 
(14.3%) with the re-injury rate of 113 horses with SDFT lesions 
(27.4%) treated with undifferentiated MSCs without PRP (28), 
a considerable difference can be observed.
A second limitation is that all the horses were treated with 
a combined therapy of PRP and MSCs, which makes it impos-
sible to evaluate the difference between the potential therapeutic 
effect of PRP in comparison to that of the tenogenically induced 
PB-derived MSCs. Therefore, future studies should focus on the 
comparison of predifferentiated with undifferentiated MSCs and 
investigate the effect of PRP addition on the clinical outcome. 
Another limitation is the difference in the rehabilitation pro-
grams between stables. Although a standardized rehabilitation 
program was given by the veterinarians to the owners to obtain 
comparable data, this program was adapted to each patient, and 
this is reflected in the C score. More precisely, in the SL group, 
75% of the horses were rehabilitating, 22.2% returned to work, 
and 2.8% returned to previous level at 6 ±  2  weeks, whereas 
42.9% were rehabilitating, 35.7% returned to work, and 21.4% 
returned to previous level at a 12 ± 4 weeks. In the SDFT group, 
88.9% of the horses were rehabilitating and 11.1% returned 
to work at 6 ±  2 weeks, whereas at 12 ±  4 weeks, 28.6% were 
rehabilitating and 71.4% returned to work. These results suggest 
that the SL heals faster than the SDFT; however, they can also 
indicate that the initial SL lesions were less severe than those of 
the SDFT. Moreover, in this study, several horses dropped out 
for long-term evaluation. The main reason for this obstacle was 
a physical move of the patient due to a change of rider, owner, 
or veterinarian. Having all the horses for the long-term evalu-
ation would have allowed us to draw more conclusions on the 
resistance to re-injury of the repaired tissue. Nevertheless, a 
large amount of horses could be identified at 12 (n = 98) and 24 
(n = 89) months after treatment and provided substantial data 
on functional recovery.
cOnclUsiOn
This study reports a safe and promising use of tenogenically 
induced allogeneic PB-derived MSCs in allogeneic PRP for the 
treatment of SL and SDFT lesions in 104 horses with statistically 
significant lower re-injury rate 2 years after treatment (P < 0.0001) 
in comparison to conventional therapies.
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